Equity Overview
Price & Market Data
Price: $3.37
Daily Change: +$0.035 / 1.04%
Daily Range: $3.26 - $3.45
Market Cap: $439,755,520
Daily Volume: 1,664,082
Performance Metrics
1 Week: 16.32%
1 Month: -5.37%
3 Months: -18.09%
6 Months: -14.32%
1 Year: -15.83%
YTD: -7.20%
Company Details
Employees: 57
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.